Clinical trials: PCI Patients, open to volunteers
Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible.
- Conditions
- Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome, Lipid Lowering, Vascular Inflammation
- Trial name
- NCT06096909
- Testing
- Tafolecimab, Cholesterol Absorption Inhibitor, Statin
- Where
- 2 sites in China
- Volunteers
- 3,684 people
- Sponsor
- China National Center for Cardiovascular Diseases
Acute Coronary Syndrome
DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid
Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at…
- Trial name
- BETA-DAPT (NCT07391358)
- Testing
- Patient decision aid to support shared decision-making between patients and clinicians
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Montreal Heart Institute
Inflammation
The Prognosis of Patients After PCI：a Multi-center Study in China
Coronary artery disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction.
- Trial name
- NCT05614050
- Where
- China
- Volunteers
- 2,400 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology